248 related articles for article (PubMed ID: 23672179)
1. Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Gallego P; Roldan V; Lip GY
Am J Respir Crit Care Med; 2013 Aug; 188(4):413-21. PubMed ID: 23672179
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
5. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
6. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
9. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2012; 15(4):776-85. PubMed ID: 22449118
[TBL] [Abstract][Full Text] [Related]
10. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
11. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
[TBL] [Abstract][Full Text] [Related]
12. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
[TBL] [Abstract][Full Text] [Related]
13. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Kovács T
Orv Hetil; 2014 Oct; 155(42):1655-60. PubMed ID: 25305723
[TBL] [Abstract][Full Text] [Related]
14. Implications of new anticoagulants in primary practice.
Perez A; Eraso LH; Merli GJ
Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
[TBL] [Abstract][Full Text] [Related]
15. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
[TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Fanikos J
J Med Econ; 2013 Oct; 16(10):1190-2. PubMed ID: 23919663
[No Abstract] [Full Text] [Related]
17. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Harris K; Mant J
Int J Clin Pract; 2013 Jul; 67(7):647-55. PubMed ID: 23621153
[TBL] [Abstract][Full Text] [Related]
18. The new oral anticoagulants in atrial fibrillation: once daily or twice daily?
Renda G; De Caterina R
Vascul Pharmacol; 2013; 59(3-4):53-62. PubMed ID: 23872195
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Akwaa F; Spyropoulos AC
Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
[TBL] [Abstract][Full Text] [Related]
20. [Evidence of novel oral anticoagulants (NOAC)].
Kitazono T
Rinsho Shinkeigaku; 2013; 53(11):992-3. PubMed ID: 24291856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
